PT791355E - METHOD FOR DECREASING DAOS ASSOCIATED WITH ISCHEMIA IN TISSUES - Google Patents

METHOD FOR DECREASING DAOS ASSOCIATED WITH ISCHEMIA IN TISSUES

Info

Publication number
PT791355E
PT791355E PT97200415T PT97200415T PT791355E PT 791355 E PT791355 E PT 791355E PT 97200415 T PT97200415 T PT 97200415T PT 97200415 T PT97200415 T PT 97200415T PT 791355 E PT791355 E PT 791355E
Authority
PT
Portugal
Prior art keywords
ischemia
daos
tissues
decreasing
mammal
Prior art date
Application number
PT97200415T
Other languages
Portuguese (pt)
Inventor
Thomas A Beyer
Delvin R Knight Jr
Banavara L Mylari
Peter J Oates
Eric R Pettipher
Wayne R Tracey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT791355E publication Critical patent/PT791355E/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The use of a sorbitol dehydrogenase inhibitor for the manufacture of a medicament for reducing tissue damage resulting from ischemia in a mammal (including a human being).
PT97200415T 1996-02-29 1997-02-13 METHOD FOR DECREASING DAOS ASSOCIATED WITH ISCHEMIA IN TISSUES PT791355E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1270896P 1996-02-29 1996-02-29

Publications (1)

Publication Number Publication Date
PT791355E true PT791355E (en) 2002-08-30

Family

ID=21756305

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97200415T PT791355E (en) 1996-02-29 1997-02-13 METHOD FOR DECREASING DAOS ASSOCIATED WITH ISCHEMIA IN TISSUES

Country Status (15)

Country Link
US (1) US5932581A (en)
EP (1) EP0791355B1 (en)
JP (1) JPH09316004A (en)
KR (1) KR100219972B1 (en)
CN (1) CN1165000A (en)
AT (1) ATE216226T1 (en)
AU (1) AU714038B2 (en)
CA (1) CA2198536C (en)
DE (1) DE69711965T2 (en)
DK (1) DK0791355T3 (en)
ES (1) ES2174176T3 (en)
IL (1) IL120271A (en)
MY (1) MY118982A (en)
PT (1) PT791355E (en)
ZA (1) ZA971715B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145364A0 (en) * 1999-04-01 2002-06-30 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
CN104346404B (en) * 2013-08-08 2018-05-18 华为技术有限公司 A kind of method, equipment and system for accessing data

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3905364A1 (en) 1989-02-22 1990-08-23 Hoechst Ag SUBSTITUTED PYRIMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A TOOL
DE4025387A1 (en) 1990-08-10 1992-02-13 Hoechst Ag SUBSTITUTED PYRIMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS REAGENTS
EP0662962A1 (en) 1992-09-28 1995-07-19 Pfizer Inc. Substituted pyrimidines for control of diabetic complications

Also Published As

Publication number Publication date
KR100219972B1 (en) 1999-09-01
CN1165000A (en) 1997-11-19
IL120271A (en) 2001-06-14
ZA971715B (en) 1998-08-27
CA2198536A1 (en) 1997-08-29
AU714038B2 (en) 1999-12-16
MY118982A (en) 2005-02-28
CA2198536C (en) 2000-06-20
DE69711965T2 (en) 2003-01-23
EP0791355A1 (en) 1997-08-27
AU1500997A (en) 1997-09-04
JPH09316004A (en) 1997-12-09
US5932581A (en) 1999-08-03
ATE216226T1 (en) 2002-05-15
EP0791355B1 (en) 2002-04-17
DK0791355T3 (en) 2002-06-17
MX9701527A (en) 1998-06-30
ES2174176T3 (en) 2002-11-01
IL120271A0 (en) 1997-06-10
KR970061257A (en) 1997-09-12
DE69711965D1 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
DE69709707T2 (en) Tissue Treatments with Controlled Release
NZ501069A (en) Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
ES2172748T3 (en) USE OF AN ALDOSA REDUCTASA INHIBITOR FOR REDUCING DAMAGE IN NON-CARDIAC TISSUE.
DE69821731D1 (en) Eye bandage for use after intraocular surgery
AU4008597A (en) The new use of dicaffeoylquinic acid for treating hepatitis b and the diseases related with retrovirus, and the new caffeoylquinic acid derivatives
DK0764157T3 (en) Benzopyrans and their use as therapeutic agents
PT983275E (en) NEW DERIVATIVES OF TRIPTOLIDO ADVANTAGES FOR THE TREATMENT OF AUTOMATIC DISEASES
PT791355E (en) METHOD FOR DECREASING DAOS ASSOCIATED WITH ISCHEMIA IN TISSUES
DE10084499T1 (en) Absorbent tissue to improve the skin's protective layer
NO953619D0 (en) Sheet for bowling ball
DE69100171T2 (en) Synergistic combination for ophthalmic use.
AR004330A1 (en) USE OF CHOLINESTERASE INHIBITORS IN THE TREATMENT OF XEROSTOMY
PT804199E (en) USE OF PENCICLOVIR FOR THE TREATMENT OF POSE HERPETICAS NEVRALGIAS
DK0711163T3 (en) Use of benzydamine in the treatment of pathological conditions caused by TNF
KR940020354U (en) Billiard cue tip grinder
SI0898562T1 (en) Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation
ITUD940156A0 (en) PROCEDURE FOR IMPROVEMENT OF THE TISSUE RAISING OPERATION AND RELATED DEVICE
IT236181Y1 (en) PERFECTED TIP FOR EYE SURGERY, IN PARTICULAR FOR THE REMOVAL OF CATARACT
BR9302334A (en) Urovarginal for patients
LV11274A (en) Tissue defects were corrected
BR7201529U (en) IMPLEMENT FOR USE IN NASAL SURGERY
ES1031273Y (en) DISPOSABLE PROTECTOR FOR HEELS AND ELBOWS IN BRANCHED PATIENTS.
ATA169694A (en) Bowling alley
BR9705688A (en) Provision of award mechanism for pool tables and the like
BR9400609A (en) Autostatic retractor for perineal and vaginal surgery